In partnership with the United States Air Force Medical Service, the University of Pittsburgh Medical Center (UPMC) has begun operating a diabetes outreach clinic at Wilford Hall Medical Center on Lackland Air Force Base in San Antonio to provide primary care and comprehensive case management for people with diabetes.
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced Otsuka has been granted exclusive rights in Japan to develop and commercialize the investigational compound saxagliptin, being studied for the treatment of Type 2 diabetes. Saxagliptin, discovered by Bristol-Myers Squibb, is a dipeptidyl peptidase-4 (DPP-4) inhibitor currently in Phase III development in the United States and Europe.
The Medicines and Healthcare products Regulatory Agency (MHRA) has identified a safety problem with certain blood glucose meters which under certain conditions display the wrong units of measurement. This could result in an insulin overdose and hypoglycaemic coma.
Symptoms of heart disease and diabetes usually seen in adults are increasingly being found in adolescents according to a longitudinal study, which suggests that reducing the intake of sugar-sweetened beverages during childhood may lessen the risk of chronic disease in later life.
The U.S. Food and Drug Administration (FDA) is providing an update to its notifications on October 13, and October 23, 2006, alerting the public to counterfeit blood glucose test strips being sold in the US for use with various models of LifeScan, Inc., One Touch Brand Blood Glucose Monitors. These test strips are used by people with diabetes to measure their blood glucose. Today?s update includes an additional lot number that is being distributed, along with a description of how to identify the new lot.
A drug commonly used to slow the loss of central vision has shown promise in stemming a common precursor of blindness in diabetics, which involves the same central light-sensitive area of retina, Johns Hopkins Wilmer Eye Institute scientists report.
Scientists at the University of Bonn have identified a new gene which could play an important role in the development of diabetes. Flies in which this hereditary factor is defective are also significantly smaller than other members of their species and live appreciably longer. In the current issue of the prestigious journal Nature the Bonn researchers have published two articles on this topic.
Children at risk of contracting juvenile diabetes may soon be vaccinated against the disease by administering insulin through a nasal spray device if a Melbourne-based clinical trial proves successful.
NICE has issued guidance to the NHS in England and Wales on the use of inhaled insulin for the treatment of diabetes (type 1 and 2).
At the American Society for Cell Biology’s 2006 conference, researchers will report that applying insulin directly to skin wounds significantly enhanced the healing process. Chronic or nonhealing wounds take an immense toll on American health and on health-care systems.